Lipocalin-2 Protein Deficiency Ameliorates Experimental Autoimmune Encephalomyelitis

Background: The role of LCN2 in EAE is not clear. Results: LCN2 expression increased in EAE. Lcn2 deficiency attenuated EAE symptoms and pathology. LCN2 enhanced glial expression of inflammatory mediators and peripheral encephalitogenic T cell activation in vitro and in vivo. Conclusion: Both central and peripheral LCN2 contributed to EAE development. Significance: LCN2 can be targeted for treatment of multiple sclerosis. Lipocalin-2 (LCN2) plays an important role in cellular processes as diverse as cell growth, migration/invasion, differentiation, and death/survival. Furthermore, recent studies indicate that LCN2 expression and secretion by glial cells are induced by inflammatory stimuli in the central nervous system. The present study was undertaken to examine the regulation of LCN2 expression in experimental autoimmune encephalomyelitis (EAE) and to determine the role of LCN2 in the disease process. LCN2 expression was found to be strongly increased in spinal cord and secondary lymphoid tissues after EAE induction. In spinal cords astrocytes and microglia were the major cell types expressing LCN2 and its receptor 24p3R, respectively, whereas in spleens, LCN2 and 24p3R were highly expressed in neutrophils and dendritic cells, respectively. Furthermore, disease severity, inflammatory infiltration, demyelination, glial activation, the expression of inflammatory mediators, and the proliferation of MOG-specific T cells were significantly attenuated in Lcn2-deficient mice as compared with wild-type animals. Myelin oligodendrocyte glycoprotein-specific T cells in culture exhibited an increased expression of Il17a, Ifng, Rorc, and Tbet after treatment with recombinant LCN2 protein. Moreover, LCN2-treated glial cells expressed higher levels of proinflammatory cytokines, chemokines, and MMP-9. Adoptive transfer and recombinant LCN2 protein injection experiments suggested that LCN2 expression in spinal cord and peripheral immune organs contributes to EAE development. Taken together, these results imply LCN2 is a critical mediator of autoimmune inflammation and disease development in EAE and suggest that LCN2 be regarded a potential therapeutic target in multiple sclerosis.

[1]  Myungwon Jin,et al.  Role of Lipocalin-2-Chemokine Axis in the Development of Neuropathic Pain following Peripheral Nerve Injury* , 2013, The Journal of Biological Chemistry.

[2]  Xiong-hao Liu,et al.  Expression of ALS‐linked TDP‐43 mutant in astrocytes causes non‐cell‐autonomous motor neuron death in rats , 2013, The EMBO journal.

[3]  K. Nakao,et al.  Secreted protein lipocalin‐2 promotes microglial M1 polarization , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  R. Bowser,et al.  Reactive astrocytes secrete lcn2 to promote neuron death , 2013, Proceedings of the National Academy of Sciences.

[5]  D. Geschwind,et al.  Lipocalin 2 is present in the EAE brain and is modulated by natalizumab , 2012, Front. Cell. Neurosci..

[6]  S. Akira,et al.  Lipocalin 2 is a novel immune mediator of experimental autoimmune encephalomyelitis pathogenesis and is modulated in multiple sclerosis , 2012, Glia.

[7]  J. A. Boer,et al.  Lipocalin 2: Novel component of proinflammatory signaling in Alzheimer's disease , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[8]  B. Barres,et al.  Genomic Analysis of Reactive Astrogliosis , 2012, The Journal of Neuroscience.

[9]  K. Suk,et al.  Regulation by lipocalin‐2 of neuronal cell death, migration, and morphology , 2012, Journal of neuroscience research.

[10]  S. Serrano,et al.  B–helper neutrophils stimulate immunoglobulin diversification and production in the marginal zone of the spleen , 2011, Nature Immunology.

[11]  K. Suk,et al.  Lipocalin-2 Is a Chemokine Inducer in the Central Nervous System , 2011, The Journal of Biological Chemistry.

[12]  E. Schiavon,et al.  Lipocalin-2 controls neuronal excitability and anxiety by regulating dendritic spine formation and maturation , 2011, Proceedings of the National Academy of Sciences.

[13]  W. Ong,et al.  Expression and localization of the iron–siderophore binding protein lipocalin 2 in the normal rat brain and after kainate-induced excitotoxicity , 2011, Neurochemistry International.

[14]  J. P. Ip,et al.  Lipocalin 2 in the central nervous system host response to systemic lipopolysaccharide administration , 2011, Journal of Neuroinflammation.

[15]  S. Akira,et al.  Lipocalin 2 Plays an Immunomodulatory Role and Has Detrimental Effects after Spinal Cord Injury , 2011, The Journal of Neuroscience.

[16]  K. Suk,et al.  Increased plasma levels of lipocalin 2 in mild cognitive impairment , 2011, Journal of the Neurological Sciences.

[17]  Christoph Preuss,et al.  Gp130-Dependent Release of Acute Phase Proteins Is Linked to the Activation of Innate Immune Signaling Pathways , 2011, PloS one.

[18]  M. E. Walker,et al.  Cutting Edge: Mast Cells Regulate Disease Severity in a Relapsing–Remitting Model of Multiple Sclerosis , 2011, The Journal of Immunology.

[19]  S. Rankin,et al.  Neutrophil kinetics in health and disease , 2010, Trends in immunology.

[20]  R. Ransohoff,et al.  Astrocyte-restricted ablation of interleukin-17-induced Act1-mediated signaling ameliorates autoimmune encephalomyelitis. , 2010, Immunity.

[21]  Fred H. Gage,et al.  Mechanisms Underlying Inflammation in Neurodegeneration , 2010, Cell.

[22]  Fatima Al-Shahrour,et al.  Changes in the pattern of DNA methylation associate with twin discordance in systemic lupus erythematosus. , 2010, Genome research.

[23]  O. Soehnlein.  An elegant defense: how neutrophils shape the immune response. , 2009, Trends in immunology.

[24]  S. Akira,et al.  Absence of functional Hfe protects mice from invasive Salmonella enterica serovar Typhimurium infection via induction of lipocalin-2. , 2009, Blood.

[25]  Fu-Tong Liu,et al.  Galectin-3 Deficiency Reduces the Severity of Experimental Autoimmune Encephalomyelitis1 , 2009, The Journal of Immunology.

[26]  K. Yudoh,et al.  Implication of granulocyte-macrophage colony-stimulating factor induced neutrophil gelatinase-associated lipocalin in pathogenesis of rheumatoid arthritis revealed by proteome analysis , 2009, Arthritis research & therapy.

[27]  Hae-Chul Park,et al.  Lipocalin-2 Is an Autocrine Mediator of Reactive Astrocytosis , 2009, The Journal of Neuroscience.

[28]  Amit Awasthi,et al.  IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells , 2008, Proceedings of the National Academy of Sciences.

[29]  A. Friedl,et al.  Neutrophil gelatinase-associated lipocalin (NGAL) is a predictor of poor prognosis in human primary breast cancer , 2008, Breast Cancer Research and Treatment.

[30]  J. Goverman,et al.  Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells , 2008, Nature Medicine.

[31]  Roland Martin,et al.  Multiple sclerosis: a complicated picture of autoimmunity , 2007, Nature Immunology.

[32]  K. Suk,et al.  A Dual Role of Lipocalin 2 in the Apoptosis and Deramification of Activated Microglia1 , 2007, The Journal of Immunology.

[33]  Bruce D. Trapp,et al.  Pathogenesis of axonal and neuronal damage in multiple sclerosis , 2007, Neurology.

[34]  S. Barnum,et al.  Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease. , 2007, Molecular immunology.

[35]  R. Ransohoff,et al.  Inflammatory Cell Migration into the Central Nervous System: A Few New Twists on an Old Tale , 2007, Brain pathology.

[36]  S. Honda,et al.  A critical role of LFA-1 in the development of Th17 cells and induction of experimental autoimmune encephalomyelytis. , 2007, Biochemical and biophysical research communications.

[37]  R. Frausto,et al.  Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice. , 2006, The American journal of pathology.

[38]  Zihua Hu,et al.  Identification of Common Transcriptional Regulatory Elements in Interleukin-17 Target Genes* , 2006, Journal of Biological Chemistry.

[39]  E. Frohman,et al.  Multiple sclerosis--the plaque and its pathogenesis. , 2006, The New England journal of medicine.

[40]  Michael R. Green,et al.  A Cell-Surface Receptor for Lipocalin 24p3 Selectively Mediates Apoptosis and Iron Uptake , 2005, Cell.

[41]  D. Ovcharenko,et al.  Neutrophil gelatinase-associated lipocalin as a survival factor. , 2005, The Biochemical journal.

[42]  T. Geijtenbeek,et al.  Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN , 2005, The Journal of experimental medicine.

[43]  S. Gaffen,et al.  Cytokines link osteoblasts and inflammation: microarray analysis of interleukin‐17‐ and TNF‐α‐induced genes in bone cells , 2005, Journal of leukocyte biology.

[44]  B. Becher,et al.  Experimental autoimmune encephalomyelitis repressed by microglial paralysis , 2005, Nature Medicine.

[45]  Shizuo Akira,et al.  Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron , 2004, Nature.

[46]  J. Köhl,et al.  The anaphylatoxins bridge innate and adaptive immune responses in allergic asthma. , 2004, Molecular immunology.

[47]  J. Travers,et al.  Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. , 2003, The Journal of allergy and clinical immunology.

[48]  R. Brutkiewicz,et al.  Myeloid marker expression on antiviral CD8+ T cells following an acute virus infection , 2003, European journal of immunology.

[49]  H. Erdjument-Bromage,et al.  An iron delivery pathway mediated by a lipocalin. , 2002, Molecular cell.

[50]  R. Liblau,et al.  Mast cells: new targets for multiple sclerosis therapy? , 2002, Journal of Neuroimmunology.

[51]  J. Goverman,et al.  A Pathogenic Role for Myelin-Specific Cd8+ T Cells in a Model for Multiple Sclerosis , 2001, The Journal of experimental medicine.

[52]  V. Wee Yong,et al.  Metalloproteinases in biology and pathology of the nervous system , 2001, Nature Reviews Neuroscience.

[53]  H. Lassmann,et al.  Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. , 2001, Immunity.

[54]  H. Tschesche,et al.  The human neutrophil lipocalin supports the allosteric activation of matrix metalloproteinases. , 2001, European journal of biochemistry.

[55]  S. Barnum,et al.  Attenuation of Experimental Autoimmune Demyelination in Complement-Deficient Mice1 , 2000, The Journal of Immunology.

[56]  D R Flower,et al.  Lipocalins: unity in diversity. , 2000, Biochimica et biophysica acta.

[57]  J. Newcombe,et al.  Expression of the β-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue , 2000, Journal of Neuroimmunology.

[58]  H. Hartung,et al.  The role of B cells and autoantibodies in multiple sclerosis , 2000, Annals of neurology.

[59]  T. Owens,et al.  IFN-γ Shapes Immune Invasion of the Central Nervous System Via Regulation of Chemokines1 , 2000, The Journal of Immunology.

[60]  D. Kolson,et al.  Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis , 2000, Multiple sclerosis.

[61]  S. Hauser,et al.  Identification of autoantibodies associated with myelin damage in multiple sclerosis , 1999, Nature Medicine.

[62]  E. Bettelli,et al.  Role of astrocytes in antigen presentation and naive T-cell activation , 1998, Journal of Neuroimmunology.

[63]  J. Cowland,et al.  Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. , 1997, Genomics.

[64]  D R Flower,et al.  The lipocalin protein family: structure and function. , 1996, The Biochemical journal.

[65]  B. Nielsen,et al.  Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases. , 1996, Gut.

[66]  Quansheng Liu,et al.  Identification of a New Acute Phase Protein (*) , 1995, The Journal of Biological Chemistry.

[67]  L. Steinman,et al.  Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. , 1994, The Journal of clinical investigation.

[68]  Y. Lee,et al.  Characterization of astrocyte nuclear proteins involved in IFN-gamma- and TNF-alpha-mediated class II MHC gene expression. , 1994, Journal of immunology.

[69]  D. Flower.  The lipocalin protein family: A role in cell regulation , 1994, FEBS letters.

[70]  R. Ransohoff,et al.  Astrocyte expression of mRNA encoding cytokines IP‐10 and JE/MCP‐1 in experimental autoimmune encephalomyelitis , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[71]  G. Opdenakker,et al.  Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders , 1992, Journal of Neuroimmunology.

[72]  I. Huitinga,et al.  The role of macrophages in demyelination , 1992, Journal of Neuroimmunology.

[73]  M. Kress,et al.  SV40-induced expression of mouse gene 24p3 involves a post-transcriptional mechanism. , 1989, Oncogene.

[74]  Mussini Jm,et al.  [Immunology of multiple sclerosis]. , 1982, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.

[75]  C. Pettinelli,et al.  Adoptive transfer of experimental allergic encephalomyelitis in SJL/J mice after in vitro activation of lymph node cells by myelin basic protein: requirement for Lyt 1+ 2- T lymphocytes. , 1981, Journal of immunology.

[76]  M. Esiri.  IMMUNOGLOBULIN-CONTAINING CELLS IN MULTIPLE-SCLEROSIS PLAQUES , 1977, The Lancet.

[77]  A. Blalock.  Surgical treatment of pulmonary stenosis. , 1947, Lancet.

[78]  J. Köhl.  Self, non-self, and danger: a complementary view. , 2006, Advances in experimental medicine and biology.

[79]  J. Tekstra,et al.  Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. , 1999, The American journal of pathology.

[80]  L. Steinman,et al.  The T lymphocyte in experimental allergic encephalomyelitis. , 1990, Annual review of immunology.